Susannah Baruch (’95), Executive Director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, authored an opinion piece for STAT examining the FDA’s recent decision not to approve Lykos Therapeutics’ application for MDMA (a psychedelic drug known as ecstasy or molly) as a treatment for post-traumatic stress disorder (“Getting to ‘Plan B’ for Psychedelic Medicine: Lessons from Reproductive Health,” Aug. 11). Citing the long road to approval faced by the emergency contraception drug known as Plan B, Susannah has “come to see these two semi-taboo areas of health care as a matched set, twins of a sort,” with “numerous legal and policy considerations and complex ethical issues” to sort out before psychedelics can be made widely available. Susannah hopes that by “embracing science” and “pursuing the highest quality evidence of safety and effectiveness,” broader acceptance of psychedelics will eventually be achieved.